Associations between erectile dysfunction, low testosterone, and cardiometabolic risk: an age stratified, propensity-matched cohort study
Erectile dysfunction and low testosterone in young men flagged 2.6-fold higher metabolic syndrome risk and responded to testosterone replacement therapy.
In a propensity-matched TriNetX cohort of 3.5 million US men, erectile dysfunction and low testosterone independently predicted incident cardiometabolic disease — with co-occurring ED+low T in young men (18-30) associated with 2.6x higher metabolic syndrome risk. Testosterone replacement therapy was associated with reduced diabetes incidence, suggesting ED and low T as early, actionable cardiometabolic risk markers.
What the study was
- Study design
- Retrospective propensity-matched cohort (TriNetX database)
- Population
- US men aged 18-70 with ED, low T, or both (n=3,494,600); stratified by age
- Sample size
- 3494600
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- International Journal of Impotence Research
Why it surfaced
Very large TriNetX cohort (n=3.5M). Age-stratified analysis and TRT subgroup add clinically actionable nuance. Confirmatory but large-scale.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.